AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27738920 — intervention group
Group type: EXPERIMENTAL
Intervention: PPIs
Number of subjects: 926
Study 27738920 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT)
Number of subjects: 926
Study 27739003 — intervention group
Group type: EXPERIMENTAL
Intervention: Two second-generation trabecular micro-bypass stents
Number of subjects: 57
Study 27739935 — intervention group
Group type: EXPERIMENTAL
Intervention: Class one (38% of participants) reported elevated needs in multiple areas.
Number of subjects: 353
Study 27739935 — intervention group
Group type: EXPERIMENTAL
Intervention: Class two (23% of participants) reported low needs.
Number of subjects: 353
Study 27739935 — intervention group
Group type: EXPERIMENTAL
Intervention: Class three (40% of participants) reported substance use and psychological needs.
Number of subjects: 353
Study 27739944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Number of subjects: 107
Study 27740536 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir-based regimen (with emtricitabine/tenofovir)
Number of subjects: 39
Study 27740633 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigenetic therapy (decitabine and panobinostat)
Number of subjects: 25
Study 27740633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasensitive sequencing approach
Number of subjects: 25
Study 27740633 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial sequencing of bone marrow samples
Number of subjects: 25
Study 27741031 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid testing approach (census, multidisease community health campaigns, home-based testing)
Number of subjects: 0
Study 27741031 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) CD4 testing
Number of subjects: 0
Study 27741031 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisease testing at CHCs
Number of subjects: 0
Study 27741031 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization
Number of subjects: 0
Study 27741031 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid testing approach
Number of subjects: 0
Study 27741195 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intrauterine devices (20% of participants)
Number of subjects: 200
Study 27741195 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine devices (46% of participants)
Number of subjects: 200
Study 27741195 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive implants (34% of participants)
Number of subjects: 200
Study 27741195 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall LARC users
Number of subjects: 200
Study 27742086 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant (part of the Icatibant Outcome Survey)
Number of subjects: 418
Study 27742126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting duration (0 to 5 hours)
Number of subjects: 2713
Study 27742581 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (1.9g/day for 12 weeks)
Number of subjects: 79
Study 27742581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 27742908 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA), 1,000 mg daily, and prednisone (P), 5 mg twice daily
Number of subjects: 11
Study 27742908 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AA+P)
Number of subjects: 11
Study 27743353 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar filgrastim (Nivestim™) as primary prophylaxis
Number of subjects: 386
Study 27743353 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar filgrastim (Nivestim™) as secondary prophylaxis
Number of subjects: 386
Study 27743353 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar filgrastim (Nivestim™)
Number of subjects: 386
Study 27743502 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA)
Number of subjects: 0
Study 27743728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound elastography
Number of subjects: 45
Study 27743860 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for purchasing prepackaged, processed meals
Number of subjects: 160
Study 27743953 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR derived from coronary computed tomography angiography (CTA)
Number of subjects: 60
Study 27744037 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine combined with microbubbles under sonication
Number of subjects: 10
Study 27744512 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient ratings of health-related quality of life (HRQOL) using SF-36 and EORTC QLQ-BN20.
Number of subjects: 246
Study 27744512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively impaired subgroup ratings.
Number of subjects: 246
Study 27744512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively intact subgroup ratings.
Number of subjects: 246
Study 27744512 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland-Altman plots for patient-proxy agreement.
Number of subjects: 246
Study 27744512 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance correlation coefficient (CCC) for HRQOL domains.
Number of subjects: 246
Study 27744512 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of perfect agreement (PD ±0).
Number of subjects: 246
Study 27744512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean difference between patients and proxies in cognitively impaired patients.
Number of subjects: 246
Study 27745744 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus itraconazole
Number of subjects: 81
Study 27745744 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus rifampin
Number of subjects: 81
Study 27745744 — intervention group
Group type: COMPARATOR
Intervention: Olaparib alone
Number of subjects: 81
Study 27746093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine response score derived from signaling conditions
Number of subjects: 91
Study 27746093 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of phosphorylated STAT (pSTAT) proteins
Number of subjects: 91
Study 27746093 — intervention group
Group type: EXPERIMENTAL
Intervention: Response capacity of naive versus memory T cell subsets to IL-6, IFN-α, IL-21, and IFN-γ
Number of subjects: 91
Study 27746690 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Ginseng (RG) supplementation for 2 weeks
Number of subjects: 14
Study 27747277 — intervention group
Group type: EXPERIMENTAL
Intervention: Single clips
Number of subjects: 0
Study 27747277 — intervention group
Group type: COMPARATOR
Intervention: Multi-firing clip device
Number of subjects: 0
Study 27747511 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) dose 6-<8 mg/week in biologic-naïve patients
Number of subjects: 5494
Study 27747511 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) dose in biologic-exposed patients
Number of subjects: 5494
Study 27747511 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased MTX doses
Number of subjects: 5494
Study 27747515 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ 4 mg/kg
Number of subjects: 213
Study 27747515 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ 8 mg/kg
Number of subjects: 213
Study 27747583 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/0.4 mL adalimumab
Number of subjects: 125
Study 27747583 — intervention group
Group type: COMPARATOR
Intervention: 40 mg/0.8 mL adalimumab
Number of subjects: 125
Study 27747585 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ-SC) 162 mg weekly or every other week for up to 84 weeks
Number of subjects: 217
Study 27748218 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential smoking-related conditions (total 120 patients)
Number of subjects: 893
Study 27748218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular disease (18 patients)
Number of subjects: 893
Study 27748218 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoplasm (6 patients)
Number of subjects: 893
Study 27748218 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory disease (67 patients)
Number of subjects: 893
Study 27748218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental disease (9 patients)
Number of subjects: 893
Study 27748218 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complication (7 patients)
Number of subjects: 893
Study 27748218 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptic ulcer disease (9 patients)
Number of subjects: 893
Study 27748218 — intervention group
Group type: EXPERIMENTAL
Intervention: Other conditions (eye condition, bony condition)
Number of subjects: 893
Study 27748745 — intervention group
Group type: EXPERIMENTAL
Intervention: METRNL overexpression
Number of subjects: 0
Study 27748745 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental downregulation of METRNL
Number of subjects: 0
Study 27748745 — intervention group
Group type: COMPARATOR
Intervention: METRNL expression in adipocytes of obese children
Number of subjects: 0
Study 27748745 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of PPARγ agonist rosiglitazone
Number of subjects: 0
Study 27748745 — intervention group
Group type: COMPARATOR
Intervention: METRNL expression in SVF cells
Number of subjects: 0
Study 27748745 — intervention group
Group type: COMPARATOR
Intervention: METRNL expression
Number of subjects: 0
Study 27749456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg every 3 weeks with 4 to 8 cycles of paclitaxel plus carboplatin, continued until progression or for up to 24 months.
Number of subjects: 1021
Study 27749456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg for more than 15 months.
Number of subjects: 1021
Study 27749456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab therapy beyond 15 months.
Number of subjects: 1021
Study 27749650 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune activation marker %CD8+CD38+DR+
Number of subjects: 31
Study 27749650 — intervention group
Group type: EXPERIMENTAL
Intervention: E-selectin, a marker of endothelial inflammation
Number of subjects: 31
Study 27749650 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary plaque
Number of subjects: 31
Study 27749683 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 164
Study 27749683 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism
Number of subjects: 164
Study 27750483 — intervention group
Group type: EXPERIMENTAL
Intervention: AT7519M (27 mg/m)
Number of subjects: 0
Study 27751676 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib, 75-mg single dose
Number of subjects: 6
Study 27751772 — intervention group
Group type: EXPERIMENTAL
Intervention: International travel to southern Asia
Number of subjects: 2001
Study 27751772 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic use during travel
Number of subjects: 2001
Study 27751772 — intervention group
Group type: EXPERIMENTAL
Intervention: Traveller's diarrhoea that persisted after return
Number of subjects: 2001
Study 27751772 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing chronic bowel disease
Number of subjects: 2001
Study 27751772 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-travel colonisation
Number of subjects: 2001
Study 27751772 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained colonisation at 12 months
Number of subjects: 2001
Study 27751772 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX-M enzyme group 9 ESBLs
Number of subjects: 2001
Study 27751772 — intervention group
Group type: EXPERIMENTAL
Intervention: Onward transmission to household members
Number of subjects: 2001
Study 27751772 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability of transmitting ESBL-E to another household member
Number of subjects: 2001
Study 27751847 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg orally once daily
Number of subjects: 210
Study 27751847 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 210
Study 27751941 — intervention group
Group type: EXPERIMENTAL
Intervention: Global fMRI signal analysis
Number of subjects: 1000
Study 27751941 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI data preparation techniques
Number of subjects: 1000
Study 27752238 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer compression bandages (2 layers)
Number of subjects: 216
Study 27752238 — intervention group
Group type: COMPARATOR
Intervention: Crepe bandages
Number of subjects: 216
Study 27752357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg two times per day
Number of subjects: 956
Study 27752357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg two times per day
Number of subjects: 956
Study 27752357 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 956
Study 27752787 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative mFOLFOX6 therapy (6 cycles)
Number of subjects: 30
Study 27754946 — intervention group
Group type: EXPERIMENTAL
Intervention: Long episodes of AT/AF
Number of subjects: 5379
Study 27754946 — intervention group
Group type: EXPERIMENTAL
Intervention: Short episodes of AT/AF
Number of subjects: 5379
Study 27754946 — intervention group
Group type: COMPARATOR
Intervention: No documented AT/AF
Number of subjects: 5379
Study 27755109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib treatment
Number of subjects: 302
Study 27755109 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 302
Study 27755463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (RV5)
Number of subjects: 0
Study 27756076 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Speckle Flowgraphy (LSFG)
Number of subjects: 20
Study 27756258 — intervention group
Group type: EXPERIMENTAL
Intervention: OXY111A (myo-inositoltrispyrophosphate)
Number of subjects: 69
Study 27756258 — intervention group
Group type: COMPARATOR
Intervention: Standard cytotoxic treatment
Number of subjects: 69
Study 27756308 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TS) prophylaxis, daily from 6 weeks of age until exclusion of HIV-infection after cessation of breastfeeding.
Number of subjects: 361
Study 27756346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored family-based intervention for improving lifestyle habits
Number of subjects: 0
Study 27756385 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary glycemic index (GI)
Number of subjects: 300
Study 27756385 — intervention group
Group type: COMPARATOR
Intervention: Lowest dietary glycemic index (GI)
Number of subjects: 300
Study 27756403 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-F scale (raw score, range 0-52)
Number of subjects: 56
Study 27756403 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-F-trans value (range 0-100)
Number of subjects: 56
Study 27756403 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitality domain (VT) of the 36-item Short-Form Health Survey (SF-36)
Number of subjects: 56
Study 27756403 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-F and VT comparison
Number of subjects: 56
Study 27756498 — intervention group
Group type: EXPERIMENTAL
Intervention: HMGB1 levels at study entry
Number of subjects: 131
Study 27756498 — intervention group
Group type: EXPERIMENTAL
Intervention: HMGB1 levels at 10 years
Number of subjects: 131
Study 27756552 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary extracorporeal perfusion for 147 ± 52 minutes (range 77-237 minutes)
Number of subjects: 8
Study 27756552 — intervention group
Group type: COMPARATOR
Intervention: Conventional reconstruction with radial forearm flaps, N=30
Number of subjects: 8
Study 27756611 — intervention group
Group type: EXPERIMENTAL
Intervention: Redo POEM
Number of subjects: 46
Study 27757240 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular warm-up program (15-min, three times per week for eleven weeks)
Number of subjects: 41
Study 27757240 — intervention group
Group type: COMPARATOR
Intervention: Regular warm-up (control group)
Number of subjects: 41
Study 27757396 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic total mesorectal excision (TME) with the assistance of single port laparoscopic surgery
Number of subjects: 12
Study 27757396 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic total mesorectal excision (TME)
Number of subjects: 12
Study 27757516 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PEEP
Number of subjects: 2377
Study 27757516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower peak inspiratory pressure
Number of subjects: 2377
Study 27757516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower plateau pressure
Number of subjects: 2377
Study 27757516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower driving pressures
Number of subjects: 2377
Study 27757516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower respiratory rate
Number of subjects: 2377
Study 27757516 — intervention group
Group type: COMPARATOR
Intervention: Lower PEEP
Number of subjects: 2377
Study 27757516 — intervention group
Group type: COMPARATOR
Intervention: Higher peak inspiratory pressure
Number of subjects: 2377
Study 27757516 — intervention group
Group type: COMPARATOR
Intervention: Higher plateau pressure
Number of subjects: 2377
Study 27757516 — intervention group
Group type: COMPARATOR
Intervention: Higher driving pressures
Number of subjects: 2377
Study 27757516 — intervention group
Group type: COMPARATOR
Intervention: Increased respiratory rate
Number of subjects: 2377
Study 27757516 — intervention group
Group type: COMPARATOR
Intervention: Fewer ICU beds
Number of subjects: 2377
Study 27757516 — intervention group
Group type: COMPARATOR
Intervention: Older age
Number of subjects: 2377
Study 27757516 — intervention group
Group type: COMPARATOR
Intervention: Active neoplasm
Number of subjects: 2377
Study 27757516 — intervention group
Group type: COMPARATOR
Intervention: Hematologic neoplasm
Number of subjects: 2377
Study 27757516 — intervention group
Group type: COMPARATOR
Intervention: Chronic liver failure
Number of subjects: 2377
Study 27757516 — intervention group
Group type: COMPARATOR
Intervention: Lower pH
Number of subjects: 2377
Study 27757516 — intervention group
Group type: COMPARATOR
Intervention: Lower PaO2
Number of subjects: 2377
Study 27757709 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists
Number of subjects: 15
Study 27757709 — intervention group
Group type: COMPARATOR
Intervention: No endothelin receptor antagonists
Number of subjects: 15
Study 27760222 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf raise exercise in patients with peripheral vascular disease
Number of subjects: 22
Study 27760222 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf raise exercise in healthy older adults
Number of subjects: 22
Study 27760437 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel hemostatic powder
Number of subjects: 0
Study 27760437 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27760529 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 42
Study 27760543 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with PSBI
Number of subjects: 37379
Study 27760543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 37379
Study 27760543 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity > 2
Number of subjects: 37379
Study 27760543 — intervention group
Group type: EXPERIMENTAL
Intervention: Late antenatal care
Number of subjects: 37379
Study 27760543 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids
Number of subjects: 37379
Study 27760543 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight
Number of subjects: 37379
Study 27760758 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking erythropoietin (EPO)-EPO receptor (R) signaling
Number of subjects: 0
Study 27760761 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplex vaccine (MVA encoding CMV antigens)
Number of subjects: 24
Study 27761518 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (self-monitoring via daily text messages, wireless devices for weight and steps tracking, 4 motivational interviewing-based phone sessions)
Number of subjects: 10
Study 27761518 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 10
Study 27762283 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche High Pure TaqMan HCV 2.0 test (HPS)
Number of subjects: 0
Study 27762283 — intervention group
Group type: COMPARATOR
Intervention: Abbott RealTime HCV RNA test (ART)
Number of subjects: 0
Study 27762283 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV RNA cutoff of 6 million IU/mL
Number of subjects: 0
Study 27762283 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of sample collection
Number of subjects: 0
Study 27763941 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRI) treatment with citalopram
Number of subjects: 2280
Study 27764091 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural pomegranate juice (POMj)
Number of subjects: 9
Study 27764091 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study 27764157 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-MNC Early group
Number of subjects: 0
Study 27764157 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-MNC Late group
Number of subjects: 0
Study 27764157 — intervention group
Group type: COMPARATOR
Intervention: Baseline myocardial viability
Number of subjects: 0
Study 27764686 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg every 2 weeks via intravenous infusion) with concurrent palliative RT
Number of subjects: 10
Study 27764800 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR2 locus variants (rs3135718)
Number of subjects: 9365
Study 27764800 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR2 locus variants (rs3135724)
Number of subjects: 9365
Study 27765666 — intervention group
Group type: EXPERIMENTAL
Intervention: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen
Number of subjects: 50
Study 27765757 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus ramucirumab (8 mg/kg)
Number of subjects: 168
Study 27765757 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 plus placebo
Number of subjects: 168
Study 27765906 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy proposed to patients (clinical trial or registered drugs)
Number of subjects: 34